Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTK2 | Q05397 | 3/20 | 0.38 |
| ▸ | TNK2 | Q07912 | 2/20 | 0.35 |
| ▸ | STK17A | Q9UEE5 | 1/20 | 0.35 |
| ▸ | BTK | Q06187 | 1/20 | 0.34 |
| ▸ | MARK3 | P27448 | 2/20 | 0.34 |
| ▸ | ACVR1 | Q04771 | 1/20 | 0.34 |
| ▸ | MARK4 | Q96L34 | 1/20 | 0.33 |
| ▸ | WEE1 | P30291 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15035271 | 0.82 | CDK4 (0.50) | TNK2 | |
| SCHEMBL15041618 | 0.77 | CDK4 (0.55) | — | |
| SCHEMBL15035487 | 0.77 | MARK3 (0.38) | PTK2TNK2BTKMARK3ACVR1 | |
| SCHEMBL15035288 | 0.73 | NUAK1 (0.37) | PTK2MARK3MARK4 | |
| SCHEMBL15035342 | 0.72 | AXL (0.33) | — | |
| SCHEMBL15035451 | 0.69 | CACNA2D1 (0.34) | PTK2 | |
| SCHEMBL15035382 | 0.68 | CDK4 (0.50) | PTK2 | |
| SCHEMBL15035550 | 0.67 | CACNA2D1 (0.36) | PTK2TNK2 | |
| SCHEMBL15035264 | 0.67 | CDK4 (0.51) | TNK2 | |
| SCHEMBL15035506 | 0.66 | TYRO3 (0.36) | PTK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20130158043-A1 | PAK INHIBITORS FOR THE TREATMENT OF CANCER | AFRAXIS, INC. (US) | 2013-06-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130158043-A1 | PAK INHIBITORS FOR THE TREATMENT OF CANCER | PAK5, PAK2, PAK6 | PTK2 12/4885TNK2 7/4885STK17A 328/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.